Literature DB >> 28591525

Pembrolizumab for Advanced Urothelial Carcinoma.

Ting Guo1, Chenchen Feng2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28591525     DOI： 10.1056/NEJMc1704612

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion.

Authors:  Shenghua Liu; Guanxiong Ding; Zhongwen Zhou; Chenchen Feng
Journal:  Onco Targets Ther       Date:  2018-04-09       Impact factor: 4.147

Review 2.  Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.

Authors:  Vikram Narayan; Andreas Kahlmeyer; Philipp Dahm; Nicole Skoetz; Michael C Risk; Connie Bongiorno; Neil Patel; Eu Chang Hwang; Jae Hung Jung; Gerald Gartlehner; Frank Kunath
Journal:  Cochrane Database Syst Rev       Date:  2018-07-23

3.  Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade.

Authors:  Yanyun Shen; Yunfeng Chen; Duoqin Wang; Zhidong Zhu
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.